Cargando…
The Ovarian Cancer Tumor Immune Microenvironment (TIME) as Target for Therapy: A Focus on Innate Immunity Cells as Therapeutic Effectors
Ovarian cancer (OvCA) accounts for one of the leading causes of death from gynecologic malignancy. Despite progress in therapy improvements in OvCA, most patients develop a recurrence after first-line treatments, dependent on the tumor and non-tumor complexity/heterogeneity of the neoplasm and its s...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7247443/ https://www.ncbi.nlm.nih.gov/pubmed/32354198 http://dx.doi.org/10.3390/ijms21093125 |
_version_ | 1783538155226398720 |
---|---|
author | Baci, Denisa Bosi, Annalisa Gallazzi, Matteo Rizzi, Manuela Noonan, Douglas M. Poggi, Alessandro Bruno, Antonino Mortara, Lorenzo |
author_facet | Baci, Denisa Bosi, Annalisa Gallazzi, Matteo Rizzi, Manuela Noonan, Douglas M. Poggi, Alessandro Bruno, Antonino Mortara, Lorenzo |
author_sort | Baci, Denisa |
collection | PubMed |
description | Ovarian cancer (OvCA) accounts for one of the leading causes of death from gynecologic malignancy. Despite progress in therapy improvements in OvCA, most patients develop a recurrence after first-line treatments, dependent on the tumor and non-tumor complexity/heterogeneity of the neoplasm and its surrounding tumor microenvironment (TME). The TME has gained greater attention in the design of specific therapies within the new era of immunotherapy. It is now clear that the immune contexture in OvCA, here referred as tumor immune microenvironment (TIME), acts as a crucial orchestrator of OvCA progression, thus representing a necessary target for combined therapies. Currently, several advancements of antitumor immune responses in OvCA are based on the characterization of tumor-infiltrating lymphocytes, which have been shown to correlate with a significantly improved clinical outcome. Here, we reviewed the literature on selected TIME components of OvCA, such as macrophages, neutrophils, γδ T lymphocytes, and natural killer (NK) cells; these cells can have a role in either supporting or limiting OvCA, depending on the TIME stimuli. We also reviewed and discussed the major (immune)-therapeutic approaches currently employed to target and/or potentiate macrophages, neutrophils, γδ T lymphocytes, and NK cells in the OvCA context. |
format | Online Article Text |
id | pubmed-7247443 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-72474432020-06-10 The Ovarian Cancer Tumor Immune Microenvironment (TIME) as Target for Therapy: A Focus on Innate Immunity Cells as Therapeutic Effectors Baci, Denisa Bosi, Annalisa Gallazzi, Matteo Rizzi, Manuela Noonan, Douglas M. Poggi, Alessandro Bruno, Antonino Mortara, Lorenzo Int J Mol Sci Review Ovarian cancer (OvCA) accounts for one of the leading causes of death from gynecologic malignancy. Despite progress in therapy improvements in OvCA, most patients develop a recurrence after first-line treatments, dependent on the tumor and non-tumor complexity/heterogeneity of the neoplasm and its surrounding tumor microenvironment (TME). The TME has gained greater attention in the design of specific therapies within the new era of immunotherapy. It is now clear that the immune contexture in OvCA, here referred as tumor immune microenvironment (TIME), acts as a crucial orchestrator of OvCA progression, thus representing a necessary target for combined therapies. Currently, several advancements of antitumor immune responses in OvCA are based on the characterization of tumor-infiltrating lymphocytes, which have been shown to correlate with a significantly improved clinical outcome. Here, we reviewed the literature on selected TIME components of OvCA, such as macrophages, neutrophils, γδ T lymphocytes, and natural killer (NK) cells; these cells can have a role in either supporting or limiting OvCA, depending on the TIME stimuli. We also reviewed and discussed the major (immune)-therapeutic approaches currently employed to target and/or potentiate macrophages, neutrophils, γδ T lymphocytes, and NK cells in the OvCA context. MDPI 2020-04-28 /pmc/articles/PMC7247443/ /pubmed/32354198 http://dx.doi.org/10.3390/ijms21093125 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Baci, Denisa Bosi, Annalisa Gallazzi, Matteo Rizzi, Manuela Noonan, Douglas M. Poggi, Alessandro Bruno, Antonino Mortara, Lorenzo The Ovarian Cancer Tumor Immune Microenvironment (TIME) as Target for Therapy: A Focus on Innate Immunity Cells as Therapeutic Effectors |
title | The Ovarian Cancer Tumor Immune Microenvironment (TIME) as Target for Therapy: A Focus on Innate Immunity Cells as Therapeutic Effectors |
title_full | The Ovarian Cancer Tumor Immune Microenvironment (TIME) as Target for Therapy: A Focus on Innate Immunity Cells as Therapeutic Effectors |
title_fullStr | The Ovarian Cancer Tumor Immune Microenvironment (TIME) as Target for Therapy: A Focus on Innate Immunity Cells as Therapeutic Effectors |
title_full_unstemmed | The Ovarian Cancer Tumor Immune Microenvironment (TIME) as Target for Therapy: A Focus on Innate Immunity Cells as Therapeutic Effectors |
title_short | The Ovarian Cancer Tumor Immune Microenvironment (TIME) as Target for Therapy: A Focus on Innate Immunity Cells as Therapeutic Effectors |
title_sort | ovarian cancer tumor immune microenvironment (time) as target for therapy: a focus on innate immunity cells as therapeutic effectors |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7247443/ https://www.ncbi.nlm.nih.gov/pubmed/32354198 http://dx.doi.org/10.3390/ijms21093125 |
work_keys_str_mv | AT bacidenisa theovariancancertumorimmunemicroenvironmenttimeastargetfortherapyafocusoninnateimmunitycellsastherapeuticeffectors AT bosiannalisa theovariancancertumorimmunemicroenvironmenttimeastargetfortherapyafocusoninnateimmunitycellsastherapeuticeffectors AT gallazzimatteo theovariancancertumorimmunemicroenvironmenttimeastargetfortherapyafocusoninnateimmunitycellsastherapeuticeffectors AT rizzimanuela theovariancancertumorimmunemicroenvironmenttimeastargetfortherapyafocusoninnateimmunitycellsastherapeuticeffectors AT noonandouglasm theovariancancertumorimmunemicroenvironmenttimeastargetfortherapyafocusoninnateimmunitycellsastherapeuticeffectors AT poggialessandro theovariancancertumorimmunemicroenvironmenttimeastargetfortherapyafocusoninnateimmunitycellsastherapeuticeffectors AT brunoantonino theovariancancertumorimmunemicroenvironmenttimeastargetfortherapyafocusoninnateimmunitycellsastherapeuticeffectors AT mortaralorenzo theovariancancertumorimmunemicroenvironmenttimeastargetfortherapyafocusoninnateimmunitycellsastherapeuticeffectors AT bacidenisa ovariancancertumorimmunemicroenvironmenttimeastargetfortherapyafocusoninnateimmunitycellsastherapeuticeffectors AT bosiannalisa ovariancancertumorimmunemicroenvironmenttimeastargetfortherapyafocusoninnateimmunitycellsastherapeuticeffectors AT gallazzimatteo ovariancancertumorimmunemicroenvironmenttimeastargetfortherapyafocusoninnateimmunitycellsastherapeuticeffectors AT rizzimanuela ovariancancertumorimmunemicroenvironmenttimeastargetfortherapyafocusoninnateimmunitycellsastherapeuticeffectors AT noonandouglasm ovariancancertumorimmunemicroenvironmenttimeastargetfortherapyafocusoninnateimmunitycellsastherapeuticeffectors AT poggialessandro ovariancancertumorimmunemicroenvironmenttimeastargetfortherapyafocusoninnateimmunitycellsastherapeuticeffectors AT brunoantonino ovariancancertumorimmunemicroenvironmenttimeastargetfortherapyafocusoninnateimmunitycellsastherapeuticeffectors AT mortaralorenzo ovariancancertumorimmunemicroenvironmenttimeastargetfortherapyafocusoninnateimmunitycellsastherapeuticeffectors |